Autoimmunity: Redoxing PTPN22 activity
A precisely tuned immune system is tremendously important for rapidly sensing and eliminating disease-causing pathogens and generating immunological memory. At the same time, immune cells need to be able to recognize the body’s own cells and distinguish them from foreign invaders. Even small dysregulations can result in the immune system attacking organs and tissues in the body by mistake, leading to conditions known as autoimmune diseases.
The incidence of autoimmune diseases worldwide has increased in recent years, leading scientists to investigate how genetic and environmental factors contribute to these pathologies (Ye et al., 2018). Amongst other findings, research has shown that an enzyme called PTPN22 (short for protein tyrosine phosphatase non-receptor type 22) is a risk factor in multiple autoimmune disorders, including rheumatoid arthritis, diabetes and systemic lupus erythematosus. PTPN22 prevents the overactivation of T-cells (cells of the adaptive immune system) by removing phosphate groups from phosphorylated proteins that are part of the T-cell receptor (TCR) signaling pathway (Figure 1; Bottini et al., 2006; Fousteri et al., 2013; Tizaoui et al., 2021).
Activation of the T-cell receptor is followed by the production of reactive oxygen species (ROS), highly reactive by-products of molecular oxygen, which can oxidize other molecules, including proteins. It is now clear that ROS have important roles in T-cell activation and that defects in ROS production may alter the immune system's responses (Simeoni and Bogeski, 2015; Kong and Chandel, 2018). However, high levels of ROS can also cause oxidative stress, leading to impaired cell activity and even death. Therefore, T-cells must optimally balance ROS production through antioxidative mechanisms and enzymes such as thioredoxin (Patwardhan et al., 2020).
Redox reactions (oxidation and its reverse reaction known as reduction) regulate many proteins, including phosphatases (Tonks, 2005), although how oxidation and reduction modulate PTPN22 activity remained unclear. Now, in eLife, Rikard Holmdahl and colleagues based in Sweden, China, Australia, Austria, France, Russia, Hungary and the United States – including Jaime James (Karolinska Institute) as first author – report that a non-catalytic cysteine may play an important role in the redox regulation of PTPN22 (James et al., 2022). Notably, this regulation was found to modulate inflammation in mouse models with severe autoimmunity.
The team genetically engineered mice that carried a mutated version of PTPN22, in which a non-catalytic cysteine at position 129 was replaced with a serine, preventing that residue from forming a disulfide bond with the catalytic cysteine at position 227 responsible for the enzymatic activity of PTPN22. Notably, this approach was based on a study in which the crystal structure of PTPN22 was examined and an atypical bond was observed between the non-catalytic cysteine at position 129 and the catalytic cysteine residue (C227; Orrú et al., 2009). In vitro experiments performed by James et al. revealed that the mutant enzyme was more sensitive to inhibition by oxidation than its wildtype counterpart. Interestingly, the results also showed that the mutant PTPN22 was less efficient at performing its catalytic role, and that it was less responsive to re-activation by antioxidant enzymes, such as thioredoxin.
To further test the role of cysteine 129 in PTPN22 redox regulation, James et al. used a mouse model that expressed the mutant protein and was susceptible to rheumatoid arthritis. These mice exhibited higher levels of inflammation in response to T-cell activation, which would be expected in animals that cannot downregulate TCR signaling. The mice also displayed more severe symptoms of arthritis, consistent with high immune activity. These effects were not observed when the experiment was repeated in mice that fail to produce high levels of ROS in response to TCR activation, confirming that the initial observations depend on the redox state of PTPN22.
Finally, James et al. performed in vitro experiments on T-cells isolated from mice carrying the mutant PTPN22. They found that when these cells became activated, the downstream targets of PTPN22 showed an increased phosphorylation status, consistent with lower PTPN22 activity.
Taken together, the elegant study of James et al. shows that cysteine 129 is critical for the redox regulation of PTPN22, and that its mutation impacts T-cell activity and exacerbates autoimmunity in mice (Figure 1). What still remains to be determined is why the mutant enzyme has lower catalytic activity, which may be due to the mutation affecting the structural conformation of PTPN22. Additionally, it will be important to assess other cysteines in PTPN22 to determine whether they are also partly involved in its redox regulation.
Understanding how the redox state of PTPN22 regulates the activity of T-cells may help researchers to develop new therapies for treating autoimmune diseases.
References
-
Role of PTPN22 in type 1 diabetes and other autoimmune diseasesSeminars in Immunology 18:207–213.https://doi.org/10.1016/j.smim.2006.03.008
-
Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunityClinical Immunology 149:556–565.https://doi.org/10.1016/j.clim.2013.10.006
-
Regulation of redox balance in cancer and T cellsThe Journal of Biological Chemistry 293:7499–7507.https://doi.org/10.1074/jbc.TM117.000257
-
A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosusHuman Molecular Genetics 18:569–579.https://doi.org/10.1093/hmg/ddn363
-
Redox regulation of regulatory T-cell differentiation and functionsFree Radical Research 54:947–960.https://doi.org/10.1080/10715762.2020.1745202
-
Redox regulation of T-cell receptor signalingBiological Chemistry 396:555–568.https://doi.org/10.1515/hsz-2014-0312
-
The role of PTPN22 in the pathogenesis of autoimmune diseases: a comprehensive reviewSeminars in Arthritis and Rheumatism 51:513–522.https://doi.org/10.1016/j.semarthrit.2021.03.004
Article and author information
Author details
Publication history
Copyright
© 2022, Shumanska and Bogeski
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 602
- views
-
- 105
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Immunology and Inflammation
How bacterial pathogens exploit host metabolism to promote immune tolerance and persist in infected hosts remains elusive. To achieve this, we show that Pseudomonas aeruginosa (PA), a recalcitrant pathogen, utilizes the quorum sensing (QS) signal 2’-aminoacetophenone (2-AA). Here, we unveil how 2-AA-driven immune tolerization causes distinct metabolic perturbations in murine macrophages’ mitochondrial respiration and bioenergetics. We present evidence indicating that these effects stem from decreased pyruvate transport into mitochondria. This reduction is attributed to decreased expression of the mitochondrial pyruvate carrier (Mpc1), which is mediated by diminished expression and nuclear presence of its transcriptional regulator, estrogen-related nuclear receptor alpha (Esrra). Consequently, Esrra exhibits weakened binding to the Mpc1 promoter. This outcome arises from the impaired interaction between Esrra and the peroxisome proliferator-activated receptor gamma coactivator 1-alpha (Ppargc1a). Ultimately, this cascade results in diminished pyruvate influx into mitochondria and, consequently reduced ATP production in tolerized murine and human macrophages. Exogenously added ATP in infected macrophages restores the transcript levels of Mpc1 and Esrra and enhances cytokine production and intracellular bacterial clearance. Consistent with the in vitro findings, murine infection studies corroborate the 2-AA-mediated long-lasting decrease in ATP and acetyl-CoA and its association with PA persistence, further supporting this QS signaling molecule as the culprit of the host bioenergetic alterations and PA persistence. These findings unveil 2-AA as a modulator of cellular immunometabolism and reveal an unprecedented mechanism of host tolerance to infection involving the Ppargc1a/Esrra axis in its influence on Mpc1/OXPHOS-dependent energy production and PA clearance. These paradigmatic findings pave the way for developing treatments to bolster host resilience to pathogen-induced damage. Given that QS is a common characteristic of prokaryotes, it is likely that 2-AA-like molecules with similar functions may be present in other pathogens.
-
- Immunology and Inflammation
We identified a novel mouse plasmacytoid dendritic cell (pDC) lineage derived from the common lymphoid progenitors (CLPs) that is dependent on expression of Bcl11a. These CLP-derived pDCs, which we refer to as ‘B-pDCs’, have a unique gene expression profile that includes hallmark B cell genes, normally not expressed in conventional pDCs. Despite expressing most classical pDC markers such as SIGLEC-H and PDCA1, B-pDCs lack IFN-α secretion, exhibiting a distinct inflammatory profile. Functionally, B-pDCs induce T cell proliferation more robustly than canonical pDCs following Toll-like receptor 9 (TLR9) engagement. B-pDCs, along with another homogeneous subpopulation of myeloid-derived pDCs, display elevated levels of the cell surface receptor tyrosine kinase AXL, mirroring human AXL+ transitional DCs in function and transcriptional profile. Murine B-pDCs therefore represent a phenotypically and functionally distinct CLP-derived DC lineage specialized in T cell activation and previously not described in mice.